Drug intelligence / Profile preview

RBX2660

Development stage: Approved
Lead developer: Ferring Pharmaceuticals
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Rectal

Overview

RBX2660 is a microbiota-based live biotherapeutic derived from screened human donor stool and formulated as a fecal microbiota suspension for prevention of recurrent *Clostridioides difficile* infection after completion of antibacterial treatment. Originally developed by Rebiotix and later advanced by Ferring Pharmaceuticals, the product works by restoring a healthier gut microbial community rather than acting through a single defined molecular target, thereby increasing colonization resistance against *C. difficile* recurrence. RBX2660 progressed through late-stage clinical development and was subsequently approved in the United States under the brand name Rebyota, becoming the first FDA-approved microbiome-based therapy for recurrent *C. difficile* infection.

Brand names: Rebyota
Other names: fecal microbiota suspension

Beyond the preview

Go deeper on RBX2660.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RBX2660.

Explore the full profile